Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG (NOVN)

158
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

UK's NICE Backs Novartis Eye Drug, Reversing Earlier Guidance

10/04/2012 | 07:16pm US/Eastern
Recommend:
0

By Marta Falconi

ZURICH--The U.K.'s health costs watchdog has reversed earlier guidance and now recommends eye drug Lucentis for a new use, after its maker Novartis AG (>> Novartis AG) offered a better price.

The U.K's National Institute for Health and Clinical Excellence, or NICE, recommends the drug for certain patients who suffer from visual impairment caused by diabetic macular oedema, the regulator said Friday. Without discount, Lucentis costs 742.17 pounds ($1,195) per injection and is given monthly, NICE said.

The new draft guidance is now up for consultation.

NICE decides if particular treatments should be used on the state-run National Health Service. The watchdog had previously rejected Lucentis for diabetic macular oedema, a condition caused by fluid collecting in the central part of the retina, which leads to blurred central vision and other problems.

The drug is already recommended to treat wet age-related macular degeneration.

Novartis said it was pleased with NICE's decision, but lamented the watchdog's move to restrict Lucentis to only those patients with more thickened retinas.

"This has undervalued the benefits that Lucentis provides to all patients with visual impairment due to diabetic macular oedema," the company said.

The Swiss company said it will continue to work with NICE and other health authorities until final draft guidance is issued by early 2013.

Lucentis, which generated nearly 2.05 billion Swiss francs ($2.19 billion) in sales in 2011, was co-developed by Novartis and Swiss rival Roche Holding AG (ROG.VX). Novartis markets the medicine outside the U.S.

Write to Marta Falconi at marta.falconi@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Novartis AG
Recommend :
0
React to this article
Latest news on NOVARTIS AG
3d ago NOVARTIS : data in The Lancet Oncology show LBH589 offers 4-month increase in me..
3d ago NOVARTIS : data in The Lancet Oncology show LBH589 offers 4-month increase in me..
3d ago Bayer hits record high on move to list plastics business
3d ago NOVARTIS : Keep eye health in vision
4d ago PAUL ALLEN : Patent Issued for Crystalline Forms of 4-Methyl-N--3-(4-Pyr-...
4d ago For Roche CEO, celebrating failure is key to success
4d ago Court grants novartis temporary injunction against ranbaxy
4d ago NOVARTIS : to tackle climate change with Sichuan tree planting project
4d ago NOVARTIS : presents oncology research advances with new data on Zykadia(TM), Afi..
4d ago NOVARTIS : presents oncology research advances with new data on Zykadia(TM), Afi..
Advertisement
Chart
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Income Statement Evolution
Novartis AG : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF